Literature DB >> 30346524

The Use of Quasi-experimental Designs for Vaccine Evaluation.

James A Lopez Bernal1,2, Nick Andrews3, Gayatri Amirthalingam1.   

Abstract

Randomized, controlled trials are not always possible to evaluate interventions targeting infectious disease. This is frequently the case when evaluating the population-level impact of vaccines or when evaluating interventions aiming to increase vaccine uptake. Under such circumstances, an array of quasi-experimental designs is increasingly being used to evaluate the effects of vaccines on a wide range of morbidity and health service outcomes. These studies can provide valuable information on the impact of vaccination programs and other related interventions in real-world settings. Nevertheless, not all quasi-experimental designs are equal, and it is important that authors and readers are aware of their relative strengths and potential sources of bias. In this paper, we discuss what a quasi-experimental design is, when they might be used for vaccine evaluation, their strengths and limitations, and examples of their application. © Crown copyright 2018.

Entities:  

Keywords:  evaluation; immunizations; interrupted time series; quasi-experimental designs; regression discontinuity

Mesh:

Substances:

Year:  2019        PMID: 30346524     DOI: 10.1093/cid/ciy906

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  6 in total

1.  Evaluating the Effectiveness of Vaccines Using a Regression Discontinuity Design.

Authors:  Nicole E Basta; M Elizabeth Halloran
Journal:  Am J Epidemiol       Date:  2019-06-01       Impact factor: 4.897

2.  Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization.

Authors:  Minal K Patel; Isabel Bergeri; Joseph S Bresee; Benjamin J Cowling; Natasha S Crowcroft; Kamal Fahmy; Siddhivinayak Hirve; Gagandeep Kang; Mark A Katz; Claudio F Lanata; Maïna L'Azou Jackson; Sudhir Joshi; Marc Lipsitch; Jason M Mwenda; Francisco Nogareda; Walter A Orenstein; Justin R Ortiz; Richard Pebody; Stephanie J Schrag; Peter G Smith; Padmini Srikantiah; Lorenzo Subissi; Marta Valenciano; David W Vaughn; Jennifer R Verani; Annelies Wilder-Smith; Daniel R Feikin
Journal:  Vaccine       Date:  2021-06-01       Impact factor: 4.169

3.  Real-World Effectiveness of Adjuvant Oxaliplatin Chemotherapy in Stage III Colon Cancer: A Controlled Interrupted Time Series Analysis.

Authors:  Wen-Kuan Huang; Hung-Chih Hsu; Shu-Hao Chang; Wen-Chi Chou; Pei-Hung Chang; Sum-Fu Chiang; John Wen-Cheng Chang; Jen-Shi Chen; Tsai-Sheng Yang; Lai-Chu See
Journal:  Front Pharmacol       Date:  2021-06-29       Impact factor: 5.810

4.  The Dutch influenza vaccination policy and medication use, outpatient visits, hospitalization and mortality at age 65.

Authors:  Tom Van Ourti; Nicolas Bouckaert
Journal:  Eur J Public Health       Date:  2020-04-01       Impact factor: 3.367

5.  Revival of ecological studies during the COVID-19 pandemic.

Authors:  Jonas Björk; Karin Modig; Fredrik Kahn; Anders Ahlbom
Journal:  Eur J Epidemiol       Date:  2021-12-24       Impact factor: 8.082

6.  Coverage for pertussis vaccination during pregnancy with 4 models of vaccine delivery: a quasiexperimental, multicentre observational study.

Authors:  Yinan Li; Nicholas Brousseau; Maryse Guay; Ève Dubé; Zineb Laghdir; Isabelle Boucoiran; Bruce Tapiéro; Caroline Quach
Journal:  CMAJ Open       Date:  2022-02-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.